Correction to: Ibalizumab: First Global Approval

Correction to: Ibalizumab: First Global Approval Drugs https://doi.org/10.1007/s40265-018-0926-2 CORRECTION Anthony Markham Springer Nature 2018 Correction to: Drugs 78(7):781–785 (2018) any noncommercial use, duplication, adaptation, distribu- https://doi.org/10.1007/s40265-018-0907-5 tion and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the The article Ibalizumab: First Global Approval, written by source, provide a link to the Creative Commons license and Anthony Markham, was originally published Online First indicate if changes were made. without open access. After publication in volume 78, issue The original article was corrected. 7, pages 781–785 Theratechnologies Inc. requested that the Open Access This article is distributed under the terms of the article be Open Choice to make the article an open access Creative Commons Attribution-NonCommercial 4.0 International publication. Post-publication open access was funded by License (http://creativecommons.org/licenses/by-nc/4.0/), which per- Theratechnologies Inc. The article is forthwith distributed mits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appro- under the terms of the Creative Commons Attribution- priate credit to the original author(s) and the source, provide a link to NonCommercial 4.0 International License (http:// the Creative Commons license and indicate if changes were made. creativecommons.org/licenses/by-nc/4.0/), which permits The original article can be found online at https://doi.org/10.1007/ s40265-018-0907-5. & Anthony Markham dru@adis.com Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs Springer Journals

Correction to: Ibalizumab: First Global Approval

Drugs , Volume OnlineFirst – May 30, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/correction-to-ibalizumab-first-global-approval-R3S02Umx48
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer Nature
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
0012-6667
eISSN
1179-1950
D.O.I.
10.1007/s40265-018-0926-2
Publisher site
See Article on Publisher Site

Abstract

Drugs https://doi.org/10.1007/s40265-018-0926-2 CORRECTION Anthony Markham Springer Nature 2018 Correction to: Drugs 78(7):781–785 (2018) any noncommercial use, duplication, adaptation, distribu- https://doi.org/10.1007/s40265-018-0907-5 tion and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the The article Ibalizumab: First Global Approval, written by source, provide a link to the Creative Commons license and Anthony Markham, was originally published Online First indicate if changes were made. without open access. After publication in volume 78, issue The original article was corrected. 7, pages 781–785 Theratechnologies Inc. requested that the Open Access This article is distributed under the terms of the article be Open Choice to make the article an open access Creative Commons Attribution-NonCommercial 4.0 International publication. Post-publication open access was funded by License (http://creativecommons.org/licenses/by-nc/4.0/), which per- Theratechnologies Inc. The article is forthwith distributed mits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appro- under the terms of the Creative Commons Attribution- priate credit to the original author(s) and the source, provide a link to NonCommercial 4.0 International License (http:// the Creative Commons license and indicate if changes were made. creativecommons.org/licenses/by-nc/4.0/), which permits The original article can be found online at https://doi.org/10.1007/ s40265-018-0907-5. & Anthony Markham dru@adis.com Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand

Journal

DrugsSpringer Journals

Published: May 30, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off